TY - JOUR
T1 - Interplay Between Immune and Cancer-Associated Fibroblasts
T2 - A Path to Target Metalloproteinases in Penile Cancer
AU - Cury, Sarah Santiloni
AU - Kuasne, Hellen
AU - Souza, Jeferson dos Santos
AU - Muñoz, Juan Jose Moyano
AU - da Silva, Jeyson Pereira
AU - Lopes, Ademar
AU - Scapulatempo-Neto, Cristovam
AU - Faria, Eliney Ferreira
AU - Delaissé, Jean Marie
AU - Marchi, Fabio Albuquerque
AU - Rogatto, Silvia Regina
N1 - Publisher Copyright:
Copyright © 2022 Cury, Kuasne, Souza, Muñoz, da Silva, Lopes, Scapulatempo-Neto, Faria, Delaissé, Marchi and Rogatto.
PY - 2022/7/19
Y1 - 2022/7/19
N2 - Extracellular matrix (ECM) remodeling and inflammation have been reported in penile carcinomas (PeCa). However, the cell types and cellular crosstalk involved in PeCa are unexplored. We aimed to characterize the complexity of cells and pathways involved in the tumor microenvironment (TME) in PeCa and propose target molecules associated with the TME. We first investigated the prognostic impact of cell types with a secretory profile to identify drug targets that modulate TME-enriched cells. The secretome analysis using the PeCa transcriptome revealed the enrichment of inflammation and extracellular matrix pathways. Twenty-three secreted factors were upregulated, mainly collagens and matrix metalloproteinases (MMPs). The deregulation of collagens and MMPs was confirmed by Quantitative reverse transcription - polymerase chain reaction (RT-qPCR). Further, the deconvolution method (digital cytometry) of the bulk samples revealed a high proportion of macrophages and dendritic cells (DCs) and B cells. Increased DCs and B cells were associated with better survival. A high proportion of cancer-associated fibroblasts (CAFs) was observed in low-survival patients. Patients with increased CAFs had decreased immune cell proportions. The treatment with the MMP inhibitor GM6001 in CAF cells derived from PeCa resulted in altered cell viability. We reported a crosstalk between immune cells and CAFs, and the proportion of these cell populations was associated with prognosis. We demonstrate that a drug targeting MMPs modulates CAFs, expanding the therapeutic options of PeCa.
AB - Extracellular matrix (ECM) remodeling and inflammation have been reported in penile carcinomas (PeCa). However, the cell types and cellular crosstalk involved in PeCa are unexplored. We aimed to characterize the complexity of cells and pathways involved in the tumor microenvironment (TME) in PeCa and propose target molecules associated with the TME. We first investigated the prognostic impact of cell types with a secretory profile to identify drug targets that modulate TME-enriched cells. The secretome analysis using the PeCa transcriptome revealed the enrichment of inflammation and extracellular matrix pathways. Twenty-three secreted factors were upregulated, mainly collagens and matrix metalloproteinases (MMPs). The deregulation of collagens and MMPs was confirmed by Quantitative reverse transcription - polymerase chain reaction (RT-qPCR). Further, the deconvolution method (digital cytometry) of the bulk samples revealed a high proportion of macrophages and dendritic cells (DCs) and B cells. Increased DCs and B cells were associated with better survival. A high proportion of cancer-associated fibroblasts (CAFs) was observed in low-survival patients. Patients with increased CAFs had decreased immune cell proportions. The treatment with the MMP inhibitor GM6001 in CAF cells derived from PeCa resulted in altered cell viability. We reported a crosstalk between immune cells and CAFs, and the proportion of these cell populations was associated with prognosis. We demonstrate that a drug targeting MMPs modulates CAFs, expanding the therapeutic options of PeCa.
KW - cancer-associated fibroblasts
KW - penile cancer
KW - response to therapy
KW - secretome
KW - transcriptome
U2 - 10.3389/fonc.2022.935093
DO - 10.3389/fonc.2022.935093
M3 - Journal article
C2 - 35928876
AN - SCOPUS:85135258233
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 935093
ER -